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The identification of cross-neutralizing antibodies to HIV-1 is important for designing antigens aimed at eliciting similar antibodies upon
immunization. The monoclonal antibody (mAb) F425-B4e8 had been suggested previously to bind an epitope at the base of V3 and shown to
neutralize two primary HIV isolates. Here, we have assessed the neutralization breadth of mAb F425-B4e8 using a 40-member panel of primary
HIV-1 and determined the epitope specificity of the mAb. The antibody was able to neutralize 8 clade B viruses (n=16), 1 clade C virus (n=11),
and 2 clade D viruses (n=6), thus placing it among the more broadly neutralizing anti-V3 antibodies described so far. Contrary to an initial report,
results from our scanning mutagenesis of the V3 region suggest that mAb F425-B4e8 interacts primarily with the crown/tip of V3, notably Ile309,
Arg315, and Phe317. Despite the somewhat limited neutralization breadth of mAb F425-B4e8, the results presented here, along with analyses from
other cross-neutralizing anti-V3 mAbs, may facilitate the template-based design of antigens that target V3 and permit neutralization of HIV-1
strains in which the V3 region is accessible to antibodies.
© 2007 Elsevier Inc. All rights reserved.Keywords: HIV-1; V3 antibody; F425-B4e8; Cross-clade neutralization; Epitope mapping; Scanning mutagenesisIntroduction
The envelope spike is the major constituent of the outer
surface of human immunodeficiency virus type 1 (HIV-1) and a
prominent target for neutralizing antibodies during HIV-1
infection (Haigwood and Stamatatos, 2003; Haynes and
Montefiori, 2006; Nabel and Sullivan, 2000; Pantophlet and
Burton, 2006; Wyatt and Sodroski, 1998; Zolla-Pazner, 2004).
However, HIV has evolved to shield conserved portions on the
two subunit glycoproteins – gp120 and gp41 – that comprise
the envelope spike from antibody. Despite an extensive regimen
of viral resistance mechanisms, the existence of a handful of
monoclonal antibodies (mAbs) that can neutralize a fairly broad⁎ Corresponding author. Fax: +1 858 784 8360.
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doi:10.1016/j.virol.2007.03.007array of primary viruses demonstrates that there are a few chinks
in the viral defensive armor (Burton et al., 2005). A molecular
understanding of regions on the HIV-1 envelope that are
conserved and sufficiently exposed on the viral spike so as to be
recognized by antibodies is an important aid in the design of
immunogens that are aimed toward the elicitation of cross-
neutralizing antibodies (Burton et al., 2004; Haynes and
Montefiori, 2006; Zolla-Pazner, 2004).
Although conserved regions on gp120, such as the CD4-
binding site or the heavily glycosylated ‘silent face’ (Wyatt et
al., 1998), are generally accepted as targets that should be
pursued for HIV vaccine design (Burton et al., 2004), some
debate exists with regard to targeting the variable loops (V1–
V5) on gp120 (Burton et al., 2004; Srivastava et al., 2004;
Zolla-Pazner, 2004). The V3 loop in particular has been a highly
discussed possible target (Hartley et al., 2005; Zolla-Pazner,
442 R. Pantophlet et al. / Virology 364 (2007) 441–4532005) ever since it was recognized as a target for neutralization
on so-called T-cell line-adapted viruses (Pantophlet and Burton,
2006). However, the inability of many anti-V3 antibodies to
neutralize HIV-1 primary isolates, coupled with the lack of an
anti-V3 mAb that is able to neutralize primary viruses as good
as the broadly neutralizing anti-gp120 mAbs b12 and 2G12, has
severely diminished interest in the V3 region as a possible
vaccine target.
The unattractiveness of the V3 region also stems from the
notion that, as a variable region, escape from antibody
neutralization will occur rapidly. Portions of the V3 region
can indeed vary considerably in sequence among viral isolates
(Catasti et al., 1995; Korber et al., 1994; LaRosa et al., 1990,
1991), but the sequence of V3 is relatively conserved at its
center, displaying a GPGR motif in many clade B viruses and a
GPGQ sequence in nearly all non-clade B viruses. This
relatively high degree of conservation likely results from the
need to preserve an important structural conformation of the V3
region so juxtaposed residues can efficiently interact with
coreceptor molecules on the cell surface (Hartley et al., 2005;
Wang et al., 1999). Based on a recent crystal structure of a V3-
containing gp120 core complexed to CD4 and an antibody V3
can be subdivided into 3 structural domains (Huang et al.,
2005): (1) the base (residues 296–300 (N-terminal portion) and
326–331 (C-terminal portion)), (2) the stem (residues 301–305
(N-terminal portion) and 321–325 (C-terminal portion)), and
(3) the tip or crown (residues 306–320). This nomenclature
differs somewhat from previous designations in the literature, in
which the base and stem regions together were denoted as the
stem (Catasti et al., 1995; Cormier and Dragic, 2002). Notably,
in the crystal structure of the V3-containing gp120 core, the V3
crown adopts the same β-turn conformation that has been
observed in the structures of anti-V3 antibodies in complex with
V3 peptides (Huang et al., 2005; Rosen et al., 2006; Stanfield et
al., 1999, 2003), thus supporting the notion that certain
structural elements in V3 are preserved in many different
viruses despite sequence variability in other portions of V3.
Although many anti-V3 antibodies neutralize only a few
HIV-1 strains, it has also become evident that some anti-V3
antibodies are able to neutralize a somewhat broader range of
viruses (Binley et al., 2004; Gorny et al., 2002, 2006). These
include mAbs such as 447-52D and 2219, which were isolated
from subtype B-infected individuals, as well as a group of more
recently described anti-V3 mAbs that were isolated from
patients infected with subtype A (Gorny et al., 2002, 2006). The
crystal structures of mAbs 447-52D and 2219 in complex with
V3 peptides demonstrate how these antibodies may be able to
neutralize a somewhat larger subset of viruses compared to
many other anti-V3 antibodies (Rosen et al., 2005; Stanfield et
al., 2004, 2006). For example, mAb 447-52D contacts the N-
terminal portion of the V3 stem via main-chain interactions and
only residues in the V3 tip via their side chains, thus being able
to tolerate some sequence variability in the N-terminal part of
the stem of different clade B viruses without a substantial
diminution in neutralizing activity (Stanfield et al., 2006). MAb
2219, in contrast, interacts mostly with conserved residues
within the N-terminal half of the stem and little with residues inthe V3 tip, which allows the antibody to tolerate sequence
variability within the tip (Stanfield et al., 2006). A panel of
recently described anti-V3 mAbs isolated from non-subtype B-
infected individuals appear to neutralize clade B viruses as good
as mAbs isolated from subtype B-infected individuals, but
appear capable of neutralizing non-B viruses somewhat better
(Gorny et al., 2006).
Pinpointing segments in V3 that are relatively conserved and
also accessible to antibody is desirable for rational antigen
design; although the neutralization breadth of anti-V3 mAbs is
somewhat limited relative to other anti-gp120 antibodies such
as b12 and 2G12 (Binley et al., 2004), it may be possible to
elicit anti-V3 antibodies with greater neutralization breadth by
targeted antigen engineering (Pantophlet and Burton, 2003).
Here, we have investigated the neutralization breadth and
epitope fine specificity of mAb F425-B4e8, which in a previous
publication was shown to neutralize 2 primary viruses and
reported to bind to a region at the base of V3 (Cavacini et al.,
2003). We show that mAb F425-B4e8 neutralizes a range of
viruses that place it in the same category as mAbs 447-52D and
2219. Furthermore, mAb F425-B4e8 does not appear to bind to
the base of V3 but, rather, seems to bind to an epitope within the
V3 crown; the predominant contact residues appear to be Ile309,
Arg315, and Phe317. The binding of mAb F425-B4e8 is not
diminished by replacing Pro313, thus suggesting that it binds
differently to the V3 tip as compared to other anti-V3 mAbs to
this segment of V3 that often require the side chain of the Pro
residue, or a precise β-turn conformation, for binding. The
binding properties of mAb F425-B4e8 may allow it to
neutralize as well as mAbs 447-52D and 2219, which makes
F425-B4e8 an interesting candidate to pursue as a template for
targeted vaccine design.
Results
Evaluation of the neutralization breadth of mAb F425-B4e8
To assess the neutralization breadth of mAb F425-B4e8, the
antibody was tested against a panel of 40 viruses in a robust and
highly sensitive pseudovirus-based single-round infectivity
assay with luciferase readout (Table 1). Assays such as these
have been shown useful for the assessment of neutralization
breadth (Binley et al., 2004; Li et al., 2005, 2006; Richman et
al., 2003). The tested viruses were picked from a previously
published 90-member panel (Binley et al., 2004) so that they
would encompass (a) different HIV clades, (b) various geo-
graphic origins, and (c) a diverse sensitivity to the previously
tested anti-V3 mAbs 447-52D and 58.2. To enable a
comparison between neutralization results obtained here and
the results obtained previously with the same viruses, mAb
F425-B4e8 was titrated beginning at the same starting
concentration of 50 μg/ml and IC50 values were determined
(Binley et al., 2004). As noted before (Binley et al., 2004), IC50
values allow for a more reliable comparison between the
potency and cross-reactivity of different antibodies. Further-
more, a 1-hour incubation time of virus plus antibody was used
as before.
Table 2
Evaluation of pseudovirus neutralization assay variability using mAb b12
Viruses Clade IC50 (μg/ml)
a
b12 (this study) b12 (Binley et al. study) b
92RW021 A 24.6 13.7
93UG077 A >50 41.1
94UG103 A 4.0 3.5
92TH006 AE 39.3 22.4
92TH022 AE >50 >50
CMU02 AE 3.5 4.3
CMU06 AE >50 >50
QH0515 B 1.6 0.7
QH0692 B 0.4 0.2
BG1168 c B >50 >50
SS1196 c B 15.3 2.7
5768-p27 B 2.2 1.3
6101-p15 B >50 >50
91US056 B 0.3 0.5
92BR020 c B 48.7 27.5
92BR021 B 3.3 2.2
92HT593 B 0.4 0.2
92HT594 c B 0.08 0.2
92US712 c B 19.0 9.2
93TH305 B 1.0 1.2
JR-CSF c B 0.3 0.2
JR-FL c B 0.04 0.09
ME1 B >50 >50
NL4.3 c B 0.1 0.06
11246-3 C 0.9 0.4
21068 C 1.3 2.3
93IN905 C 23.7 34.2
93IN999 C 4.4 4.1
93MW959 C >50 >50
93MW960 C 0.2 0.2
97ZA012 C >50 >50
98BR004 C >50 >50
98CN006 C 15.2 8.4
98CN009 C 1.0 0.6
98IN022 C 0.4 0.04
92UG001 D 0.7 1.2
92UG005 D >50 >50
92UG024 D >50 49.1
92UG035 D >50 >50
92UG046 D 0.1 0.2
94UG114 D >50 >50
aMLV N/A >50 >50
a IC50 values below 50 μg/ml are denoted in bold type.
b Information taken from Binley et al. (2004).
c Molecular clone.
Table 1
Neutralization of a panel of 40 pseudotyped HIV-1 by mAb F425-B4e8
Virus a Clade b IC50 (μg/ml)
c
92RW021 A >50
93UG077 A >50
94UG103 A >50
92TH006 AE >50
92TH022 AE >50
CMU02 AE >50
CMU06 AE >50
QH0515 B >50
QH0692 B 4.1
BG1168 d B >50
SS1196 d B 34.6
5768-p27 B >50
6101-p15 B >50
91US056 B >50
92BR020 d B 0.4
92BR021 B >50
92HT594d B 4.3
92US712 d B >50
93TH305 B 37.4
JR-CSFd B 7.2
JR-FL d B 2.4
ME1 B >50
NL4.3 d B 14.0
11246-3 C >50
21068 C >50
93IN905 C >50
93IN999 C >50
93MW959 C >50
93MW960 C 49.7
97ZA012 C >50
98BR004 C >50
98CN006 C >50
98CN009 C >50
98IN022 C >50
92UG001 D >50
92UG005 D 22.9
92UG024 D >50
92UG035 D >50
92UG046 D 35.1
94UG114 D >50
aMLV N/A >50
a All viruses are quasispecies pools except where denoted. Virus designations
are generally denoted as year (of isolation), country (of isolation), and name/
number. aMLV, amphotrophic murine leukemia virus.
b AE, circulating recombinant form_AE01. N/A, not applicable.
c IC50 values below 50 μg/ml are denoted in bold type.
d Molecular clone.
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B viruses, 1 clade C virus, and 2 clade D viruses. Overall, the
neutralization potency of the antibody was low, which contrasts
with the higher potencies observed with certain other anti-V3
antibodies (Binley et al., 2004; Li et al., 2005). Interestingly,
mAb F425-B4e8 was able to neutralize virus 92BR020, which
was not neutralized previously by mAb 447-52D (Binley et al.,
2004). However, virus 92BR020 was tested previously as a
quasispecies pool, whereas in the current study it was tested as a
molecular clone. Although this clone was selected because
sensitivity of the virus to neutralization by mAbs b12, 2G12,
2F5, 4E10 and HIV+ serum N16 generally resembled that of the
quasispecies pool (T. Wrin, R. Pantophlet, C. Petropoulos, D.R.Burton, unpublished results), the clone has not been tested with
mAb 447-52D. Thus, it is possible that the selected clone differs
in its sensitivity to anti-V3 antibodies as compared to the
quasispecies pool.
We next assessed the neutralization breadth of mAb F425-
B4e8, by comparing the neutralization results obtained in this
study with mAb F425-B4e8 to those obtained previously with
mAb 447-52D in the study by Binley et al. (2004); direct
comparison of the antibodies in one assay was not possible in
this study due to the inability to procure sufficient 447-52D
antibody for neutralization assays. For the comparison between
studies, we first evaluated assay reproducibility using mAb b12.
For most viruses, the results obtained here were in good
Table 3
Comparison of the neutralization breadth of mAbs F425-B4e8 and 447-52D
Viruses Clade IC50 (μg/ml)
a
F425-B4e8 447-52Db
92RW021 A >50 >50
93UG077 A >50 >50
94UG103 A >50 >50
92TH006 AE >50 >50
92TH022 AE >50 >50
CMU02 AE >50 >50
CMU06 AE >50 >50
QH0515 B >50 >50
QH0692 B 4.1 40.3
5768-p27 B >50 >50
6101-p15 B >50 >50
91US056 B >50 >50
92BR021 B >50 >50
92HT593 B 22.1 >50
92HT594 B 4.3 7.9
93TH305 B 37.4 8.5
JR-CSF B 7.2 >50
JR-FL B 2.4 32.6
ME1 B >50 >50
NL4.3 B 14.0 0.07
11246-3 C >50 >50
21068 C >50 >50
93IN905 C >50 >50
93IN999 C >50 >50
93MW959 C >50 >50
93MW960 C 49.7 >50
97ZA012 C >50 >50
98BR004 C >50 >50
98CN006 C >50 >50
98CN009 C >50 >50
98IN022 C >50 >50
92UG001 D >50 >50
92UG005 D 22.9 32.2
92UG024 D >50 >50
92UG035 D >50 >50
92UG046 D 35.1 >50
94UG114 D >50 >50
aMLV N/A >50 >50
a IC50 values below 50 μg/ml are denoted in bold type.
b Results taken from Binley et al. (2004).
444 R. Pantophlet et al. / Virology 364 (2007) 441–453agreement with the results obtained in the Binley et al. study
(Table 2); that is, there was less than a 1-dilution step difference
between IC50 titers. The most noticeable difference was
observed with virus SS1196, which was 5× more resistant to
b12 in this study than in the Binley et al. study (Table 2). Like
virus 92BR020 described above, virus SS1196 was also used
here as a molecular clone, whereas it was used previously as a
quasispecies pool. The SS1196 clone is similarly sensitive to
neutralization by mAbs 2G12, 2F5, and 4E10, but 5–6× more
resistant to mAb b12 and at least 5× more resistant to serum
N16 (T. Wrin et al., unpublished results). Whether these
variations in neutralization sensitivity are due to sequence
differences is currently being investigated and will be presented
elsewhere.
Given these discrepancies and to allow for a proper com-
parison between mAbs F425-B4e8 and 447-52D, we did not
compare the neutralization titers of the four viruses that had
been used previously as a quasispecies pool and that were used
here as molecular clones (i.e., SS1196, BG1168, 92BR020, and
92US712). Comparison of the remaining viral isolates shows
that the neutralization breadth of mAb F425-B4e8, though
limited, is comparable to that of mAb 447-52D (Table 3).
However, their respective potencies often differ depending on
the virus. Of note is that mAb F425-B4e8 neutralized the
primary virus JR-CSF (IC50 ∼7 μg/ml), whereas 447-52D
failed to neutralize the same virus in the previous study (Binley
et al., 2004). As noted in that study, the inability of mAb 447-
52D to neutralize JR-CSF in the U87 target cell-based
pseudovirus assay was perhaps surprising, given that the
antibody has been reported to neutralize JR-CSF virus in a
single-round PBMC-based assay (Gorny et al., 2004). However,
mAb 447-52D notably failed to neutralize JR-CSF in recent
pseudovirus and PBMC-based assays (Eda et al., 2006a,
2006b). Regardless of the underlying reason for these
discrepancies, the potency with which mAb F425-B4e8 is
able to neutralize JR-CSF demonstrates that this moderately
neutralization-resistant virus – and the closely related virus JR-
FL – can be neutralized well by select anti-V3 antibodies.
Effect of single-residue substitutions in the V3 region of
gp120JR-CSF on binding of mAb F425-B4e8 to monomeric
gp120
We next sought to define the epitope specificity of mAb
F425-B4e8. Defining the epitopes recognized by anti-V3
antibodies has traditionally been accomplished with V3
peptides in ELISA binding assays (e.g., Pepscan) and competi-
tion studies, or by determining the ability of the antibodies to
bind a series of recombinant gp120s with varying V3 regions
(for example, Eda et al., 2006b; Gorny et al., 1992, 1998;
Laisney and Strosberg, 1999; Moore et al., 1994, 1995;
Schreiber et al., 1997; Seligman et al., 1996; White-Scharf et
al., 1993). In some instances, the results derived from these
studies have been confirmed by analyzing peptide sequences
selected with antibody from peptide phage display libraries
(Keller et al., 1993) or by comparing the ability of antibodies to
neutralize viruses with various V3 sequences (e.g., Moore et al.,1995; Zolla-Pazner et al., 2004). The results of mapping studies
with peptides have generally agreed with the results from X-ray
crystallography and NMR studies (Rosen et al., 2005; Rosen et
al., 2006; Sharon et al., 2003; Stanfield et al., 2003, 2004,
2006). However, it is not possible to assess the energetic
contribution of a given residue side chain to binding affinity
from structural results alone (Cunningham and Wells, 1993;
Dall'Acqua et al., 1998; Seligman et al., 1996) and results from
antibody binding assays with peptides as solid-phase antigens
are not always good predictors of antibody binding to V3
regions in the context of gp120 (Gorny et al., 2002; Moore,
1993; Moore et al., 1994).
Here, we opted for a scanning mutagenesis approach to
identify specific side chains that are required for antibody
binding. Site-directed mutagenesis has been used extensively
within the HIV field as well as numerous other systems to
analyze the interaction between ligands (for example, Calarese
445R. Pantophlet et al. / Virology 364 (2007) 441–453et al., 2003; Cunningham et al., 1989; Cunningham and Wells,
1989, 1993; Dall'Acqua et al., 1998; Darbha et al., 2004; Lu et
al., 2001; Olshevsky et al., 1990; Pantophlet et al., 2003;
Rizzuto et al., 1998; Scanlan et al., 2002; Thali et al., 1991,
1992; Vajdos et al., 2002; Wang et al., 1999; Weiss et al., 2000;
Zwick et al., 2003, 2004, 2005). For our approach, single
residues were mutated individually to Ala. Alanine is a good
replacement residue because it eliminates the side chain beyond
the β carbon but, in general, does not substantially alter the
main chain protein conformation (aside from only small and
very local structural perturbations), cause steric effects, or
impose major electrostatic changes (Cunningham and Wells,
1989, 1993; Pal et al., 2003). More importantly, similar alanine
mutagenesis approaches have been used to identify residues in
V3 that are involved in coreceptor binding and viral infectivity
(Suphaphiphat et al., 2007; Wang et al., 1999). The Arg residue
at position 315 was also mutated to Gln so as to generate a
GPGQ sequence in V3 akin to non-subtype B viruses and, thus,
to better assess the possible requirement of the Arg at position
315 for the binding interaction of mAb F425-B4e8.
Ideally, we would have preferred to perform our analysis in
the context of the virus by investigating the ability of the mAb
to neutralize single-mutant viruses. This type of approach has
been employed for structure–function analyses of interhelical
interactions in gp41 (Lu et al., 2001) and, more recently, for
studying the epitopes of the anti-gp41 antibodies 2F5 and 4E10
(Zwick et al., 2005) and a panel of anti-V3 mAbs (Krachmarov
et al., 2006). However, we were not surprised to observe that
not all alanine mutants were infectious (Fig. 1) as several of the
mutated residues, such as Arg298, Lys305, Ile307, and Phe317,
have been shown to be important for viral infectivity and
binding to the CCR5 coreceptor on target cells (Rizzuto et al.,
1998; Suphaphiphat et al., 2007; Wang et al., 1999).Fig. 1. Influence of V3 mutations on viral infectivity of U87·CD4·CCR5-positive ce
env-deficient, luciferase-expressing HIV-1 provirus (pNL4.3Luc) along with a plasm
The recombinant viruses were used to infect target cells with equal volumes of virus su
relative luciferase units and ranges are shown.Discrepancies between the infectivity of mutant viruses in
this study compared to the studies by Wang et al. and
Suphaphiphat et al. may be related to the use of different
viruses and systems. For example, in the Wang et al. study a
virus was used that expresses a consensus B gp120 (Wang
et al., 1999) and virus JR-FL was used in the study by
Suphaphiphat et al. (2007), whereas virus JR-CSF was used
here; although viruses JR-FL and JR-CSF have very similar
amino acid sequences, the minor sequence differences may be
sufficient to affect the infectivity of mutant viruses. Further-
more, pseudoviruses were incubated for 3 days with target cells
in our study, whereas viruses were cultured for 7 days with
target cells in the other two studies.
Given our inability to use all mutant viruses in infectivity
assays, we opted to perform our analyses on solubilized gp120
derived from pseudotyped viruses, as was done in previous
studies using anti-gp120 antibodies (Pantophlet et al., 2003;
Scanlan et al., 2002). However, it is well-known that disruption
of binding does not unequivocally prove that a residue is part of
the antibody epitope (Cunningham andWells, 1989); the alanine
scan only identifies side chains that most affect the binding
interaction, whereas crystallographic analysis of the antibody–
antigen complex would be required to determine how this may
occur (Cunningham and Wells, 1993). Gp120 from virus JR-
CSF was used as a template for mutagenesis, given that mAb
F425-B4e8 was able to neutralize this virus well (Table 1) and
binds monomeric gp120JR-CSF with high affinity (data not
shown). Based on the ELISA binding curves, apparent antibody
binding affinities were determined and related to the apparent
antibody affinity for wild-type gp120JR-CSF. Substitutions that
decreased antibody binding 10-fold or more (≤10% apparent
affinity relative to wild type) were considered indicative of
having removed a side chain that is critical for antibody binding,lls. Pseudovirions were generated by transient transfection of 293T cells with an
id expressing either mutant or wild-type (w.t.) JR-CSF envelope glycoprotein.
pernatant. The assay was done in triplicate (w.t.) or sextuplicate (mutants). Mean
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446 R. Pantophlet et al. / Virology 364 (2007) 441–453whereas mutations that enhanced binding 2-fold or more
(≥200% apparent affinity relative to wild type) were considered
indicative of having removed a side chain that, directly or
allosterically, hinders antibody binding. Intermediate values
were recorded as having either moderate (11–50% apparent
affinity relative to wild type) or no considerable influence on
antibody binding (51%–200% apparent affinity relative to wild
type). These parameters were derived from previous studies that
have used mutagenesis to assess the energetic contribution of
side chains in protein–protein interactions, including the binding
of antibodies to antigen, by measuring the loss (or gain) in
binding free energy (ΔΔG) upon residue substitution (Cunning-
ham and Wells, 1989; Dall'Acqua et al., 1996; Pal et al., 2003).
In these studies, a loss (or gain) of at least 1 kcal/mol is
considered significant and changes of 2.5 kcal/mol or greater are
considered critical (also termed ‘hot spots’) (Dall'Acqua et al.,
1996). TheseΔΔG values correspond to a change inmonovalent
binding affinity of approximately 3-fold and 12-fold, respec-
tively. However, to correct for possible bivalent binding of IgG
in our ELISA system used here, 2-fold and 10-fold changes in
affinity were chosen as the cut-off parameters. Our parameters
were purposely set conservatively; bivalent interactions can
greatly increase the antibody–antigen binding interaction, thus
leading to an apparent binding affinity when measured by
ELISA that is several folds greater than the true binding affinity
(Azimzadeh et al., 1992; Stevens, 1987).
A total of 18 mutants containing single Ala substitutions and
1 mutant containing a Gln substitution were generated. The
locations of the substitutions spanned nearly the entire V3
region (residues 298–325, Table 4), though most altered
residues encompass the N-terminal portion of the stem and
V3 tip. The two Gly residues located within the β hairpin turn of
V3 were not altered to avoid a more substantial alteration of the
conformation of the V3 tip upon their replacement by the larger
Ala residue. As noted previously by Cunningham and Wells
(1989), the contribution of glycine residues to ligand binding
cannot be properly assessed by mutagenesis except with larger
or more conformationally disruptive substitutions. However,
given that most antibody–antigen interactions are dominated by
side-chain interactions (Davies and Cohen, 1996), we con-
sidered it unlikely that the side chains of the two glycine
residues would contribute significantly to the interaction with
antibody.
The binding profile of mAb F425-B4e8 showed that the
binding affinity of the antibody is not affected by mutating
Pro313 to Ala (Table 4). However, F425-B4e8 binding is
dependent on the presence of the Arg315 side chain; replacement
of Arg315 with Ala or Gln severely diminished antibody binding
(Table 4). The antibody also bound with diminished affinity to
mutants I309A and F317A relative to wild-type gp120JR-CSF.
Strikingly, binding of mAb F425-B4e8 was not enhanced or
diminished more than 1.5-fold by any of the other mutations
(Table 4), suggesting that it probably binds mainly to the tip of
the V3 region with little or no interaction with residues in the
stem, although the possibility of main-chain interactions cannot
be excluded due to the inability of the alanine scan to assess this
type of interaction (Cunningham and Wells, 1989). The map of
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notion that it bound to an epitope at the base of V3, which was
concluded based on the seeming ability of mAb F425-B4e8 to
bind a gp120 mutant in which only a distal portion of the V3
region was deleted (Cavacini et al., 2003). However, a review of
those experiments has revealed that this is not the case and
follow-up experiments using immunoprecipitation assays have
supported the results obtained in our study (J. Sodroski, personal
communication).
The inability of mAb F425-B4e8 to neutralize a few of the
clade B viruses is in good agreement with the scanning
mutagenesis, which showed that residues Ile309, Arg315, and
Phe317 are critical for binding. As shown in Table 5, viruses
5768-p27, 92BR021, and 6101-p15 contain a Met instead of an
Ile at position 309; the thioether group of the Met presumably
disrupts the interaction with antibody. In virus 5768-p27, the
Ala at position 316 is also replaced by the larger Val, which may
distort the spacing between Arg315 and Phe317. In viruses 6101-
p15, 91US056, and ME1, Arg315 is replaced by either an Ala or
a Gly, whereas in viruses QH0515, ME1, and BG1168, Phe317
is substituted (Table 5). Only for virus 92US712 are there no
substitutions in the putative antibody epitope that would readily
explain the inability of F425-B4e8 to neutralize this virus well.
However, we presume that the occurrence of a charged residue
(Lys) at position 328 in virus 92US712 relative to the
uncharged Gln residue in JR-CSF may influence the conforma-
tion of V3 and so affect the affinity of the antibody for its
epitope (Table 5). However, mAb F425-B4e8 did neutralize
virus 92US712 to ∼40% at the highest antibody concentration
tested in this study (50 μg/ml; result not shown). Whether the
inability of F425-B4e8 to neutralize this virus is also related to
accessibility constraints imposed by other regions of the virus,
e.g., V1/V2 (Krachmarov et al., 2005, 2006; Pinter et al., 2004),
remains to be investigated. However, it has become clear that
the presence of the core epitope of an antibody in the linear
envelope sequence does not assure neutralization. This is notTable 5
Comparison of V3 sequences of clade B viruses that were not neutralized by
mAb F425-B4e8 to the V3 sequence of JR-CSF
aDashes denote amino acid homology to the V3 of JR-CSF. Spaces represent a
deletion relative to JR-CSF. Mutation of Arg315 (double underline) to Ala
severely diminishes F425-B4e8 binding whereas changing Ile309 or Phe317
(single underline) to Ala moderately decreases binding affinity. Sequence
alignment was performed using ClustalW (http://www.ebi.ac.uk/clustalw/) and
formatted for publication using SeqPublish (http://www.hiv.lanl.gov/content/
hiv-db/SeqPublish/seqpublish.html).only the case for anti-V3 antibodies but has also been dem-
onstrated with antibodies to other regions. For example, in a
previous study (Binley et al., 2004), it was shown that the cross-
neutralizing anti-gp41 mAb 2F5 was unable to neutralize some
viruses despite the presence of the ELDKWA epitope in these
viruses (the antibody core epitope DKW is underlined),
indicating that the binding of mAb 2F5 to its epitope may
also be prevented by quaternary constraints within the context
of the viral spike.
For mAb 447-52D, used here as a control to gauge the effects
of the amino acid substitutions, replacing Arg315 with either Ala
or Gln reduced antibody binding affinity substantially (Table 4).
This observation is in agreement with previous mapping studies
(Gorny et al., 1992; Keller et al., 1993) as well as NMR and
crystallographic analyses of this antibody in complex with a V3
peptide (Rosen et al., 2005; Stanfield et al., 2004). Alanine
substitution of residues at positions 304–309, 313, and 319–
320 moderately diminished the binding affinity of 447-52D.
Pro313 in the V3 sequence is important for proper 447-52D
binding interactions (Stanfield et al., 2004) and, thus, a
reduction in binding affinity upon mutation to Ala was not
surprising. The other reductions were somewhat striking, given
that mAb 447-52D interacts for the most part via main-chain
contacts with the V3 region; Ala substitutions would not be
expected to affect main-chain interactions (Cunningham and
Wells, 1989). However, in the NMR structure of mAb 447-52D
with a V3 peptide (Sharon et al., 2003), the formation of the β
hairpin is stabilized by an extensive network of hydrogen bonds
and hydrophobic interactions between the N- and C-terminal
segments of the V3 stem. Covariation within the V3 region
suggests that these interactions likely play a role in stabilizing
the V3 loop (Korber et al., 1993). In the case of mAb 447-52D,
these interactions may also be conducive to high-affinity
antibody binding as they likely stabilize the β-strand–β-strand
interaction between the antibody heavy chain and V3 (Stanfield
et al., 2004); substitution of individual residues flanking the β
hairpin turn (without compensatory mutations in the opposite
flank) likely distorts this bonding network, thus affecting 447-
52D binding affinity.
Effect of select single-residue substitutions in the V3 region on
virus susceptibility to neutralization by mAb F425-B4e8
As noted above, we would have preferred to perform our
mutagenesis analyses in the context of the virus. However, this
was not pursued due to the diminished and, in some instances,
severely impaired infectivity of the mutant viruses relative to
wild-type virus (Fig. 1); we reasoned that the lowered
infectivity of the viruses might obscure the effects of the
mutations on antibody neutralization. In the case of mAb F425-
B4e8 in particular, we could not test mutant viruses I309A and
F317A due to their substantially reduced level of infectivity.
However, because mAb F425-B4e8 bound gp120 with muta-
tions at position 315 (Arg) poorly, we did test the corresponding
viruses (R315A and R315Q) for neutralization sensitivity to the
antibody, given also that the infectivity of these viruses was
least impaired by the introduced mutations. Both viruses were
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virus R315Awas neutralized to only 30% and virus R315Q was
neutralized to 19% at the highest concentration of antibody
tested here (50 μg/ml), whereas wild-type virus was neutralized
at >80% at the same concentration (data not shown). This
change in neutralization sensitivity seemed to be limited to the
V3 region, given that the neutralization sensitivity of the viruses
to mAb b12 remained unchanged (data not shown).
Discussion
Variation in the neutralization breadth of anti-V3 antibodies
to HIV-1 is influenced by the fine specificity of the respective
antibody vis-à-vis overlap of the antibody epitope with
conserved portions of the V3 region that are accessible to the
antibody on virions. The aim of this study was to comprehen-
sively assess the neutralization breadth and epitope fine
specificity of mAb F425-B4e8 so as to further identify residues
within the V3 region that are accessible to antibody on primary
viruses and that, thus, might pinpoint segments in V3 that can
become targets for rational HIV vaccine design. Although mAb
F425-B4e8 had been shown previously to neutralize 2 primary
viruses, its neutralization breadth had not been analyzed to date.
Here, we determined that this antibody is able to neutralize a
modest fraction of viruses (Table 1) and that the neutralizing
activity seems at least as good as that of mAb 447-52D, which is
considered among the more broadly neutralizing anti-V3
antibodies (Binley et al., 2004; Zolla-Pazner et al., 2004).
However, other anti-V3 mAbs have been described more
recently that seem to neutralize as well as or even more broadly
than mAb 447-52D. MAb 2219, for example, initially did not
appear to neutralize as broadly as mAb 447-52D (Gorny et al.,
2004, 2002; Li et al., 2005), but in a more recent study by Gorny
et al., using a different selection of viruses, seems to neutralize
equivalently to mAb 447-52D (Gorny et al., 2006). In this latter
study by Gorny et al., a panel of anti-V3 mAbs is also described
that were isolated from subtype A-infected individuals and thatFig. 2. Effects of single-residue substitutions on binding of mAbs F425-B4e8 and
structure of gp120JR-FL-core+ V3 (Huang et al., 2005) (only the V3 portion of the stru
are colored and labeled (i.e., <50% affinity relative to wild type). As in Table 4, su
affinity relative to wild type), and those colored red caused a strong decrease in b
produced using the UCSF Chimera package (http://www.cgl.ucsf.edu/chimera) from
of California, San Francisco. The resulting images were labeled and compiled withseem to neutralize somewhat better than mAb 447-52D (Gorny
et al., 2006). However, these mAbs have only been tested on a
relatively small panel of viruses so far (in the Gorny et al. study
only 11 viruses were tested); thus, it is possible that if other or
additional virus strains were included, such as the viruses
described in this study, then the neutralization breadth of 447-
52D and these antibodies would be similar. In this regard it is
worth noting that statistical significance was not achieved in the
Gorny et al. study between the neutralization breadth of mAb
447-52D and the newly described panel of non-B anti-V3 mAbs
(Gorny et al., 2006).
The ability of mAb F425-B4e8 to neutralize a relatively
larger number of viruses may stem from its apparent indepen-
dence of a precise β-turn conformation at the V3 tip, as evi-
denced by its ability to bind mutant P313A. Furthermore, the
apparent binding affinity of mAb F425-B4e8 relative to wild-
type gp120 was not substantially enhanced by any of the Ala
substitutions. At present it is not possible to exclude the possi-
bility that, like mAb 447-52D, F425-B4e8 interacts with the
stem of V3 via main-chain interactions which cannot be reveal-
ed by alanine mutagenesis (Cunningham and Wells, 1989).
The vulnerability of HIV to some anti-V3 antibodies that
seem to bind mainly the tip segment of V3 is supported by the
recently described mAb KD-247, which interacts mainly with
residues IGPGR and is not influenced much by mutations in
flanking residues (Eda et al., 2006b), and by mAb 447-52D,
which has been shown to interact with V3 in a manner that
encompasses mainly the tip of V3 (Stanfield et al., 2004). The
moderate decrease in binding of mAb 447-52D to several
mutants along the N-terminal portion of the V3 stem (Fig. 2)
suggests that it is affected more by the destabilization of the
hydrogen-bonding network between the N- and C-terminal
segments of the V3 stem than mAb F425-B4e8.
MAb F425-B4e8 did not neutralize most non-clade B viruses
with a Gln instead of an Arg at position 315, as would be
expected based on the mutagenesis. However, although the
affinity of the antibody for mutant R315Q was >20-fold lower447-52D. Results from mutagenesis analyses (Table 4) were mapped onto the
cture is depicted). Only substitutions that substantially affected antibody binding
bstitution of residues colored blue had a moderate effect on binding (10–50%
inding (<10% affinity relative to wild type). Molecular graphics images were
the Resource for Biocomputing, Visualization, and Informatics at the University
Adobe Photoshop CS (v. 8.0).
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(>10 μg/ml) did achieve an absorbance that was equal to wild
type (data not shown), thus explaining perhaps in part its ability
to weakly neutralize viruses 93MW960 (IGPGQTF) and
92UG046 (IGLGQAY), which both have GPGQ sequences in
V3, as well as mutant virus R315Q. Of the two non-clade B
viruses tested here that contain an Arg at position 315 (92UG005
and 92UG035), only one, virus 92UG005 (IGPGRAY), was
neutralized. These observations support the hypothesis that in
non-B viruses the conformation of V3 may be somewhat
different than in clade B viruses (Gorny et al., 2006; Liao et al.,
2006; Stanfield et al., 2006).
The V3 region of HIV-1 gp120 is arguably a potential target
for HIV vaccine design (Zolla-Pazner, 2005). It is often
presumed that the inability of anti-V3 antibodies to neutralize
broadly is largely due to limited accessibility of the V3 region to
antibody when V3 is in the context of the functional envelope
spike on the viral surface. Indeed, recent studies have shown that
V3 may be shielded – at least in part and on certain viruses – by
the V1/V2 region (Krachmarov et al., 2006; Pinter et al., 2004),
thus supporting the results from earlier investigations into the
functional properties of V1/V2 (Cao et al., 1997; Wyatt et al.,
1993). However, it should also be noted that sequence
variability in the regions flanking the conserved β-turn in the
V3 crown (GPGR sequence) may alter the stability of the turn or
alter its surface accessibility (Catasti et al., 1995). The influence
of V1/V2 and sequence variation in V3 on the binding inter-
action of mAb F425-B4e8 with V3 will be subject to further
investigation.
Whether an antigen can be designed that elicits antibodies
that bind exclusively to the tip of V3, similarly to mAb F425-
B4e8 but perhaps with greater neutralization breadth, cannot
be answered currently. We are seeking to solve the structure of
this antibody in complex with V3 peptides and gp120 to gain
further insight into its mode of binding at the atomic level. The
crystallographic results will be useful in generating variants of
mAb F425-B4e8 that (a) are able to bind clade B viruses more
potently and/or (b) are able to bind V3 sequences with a
GPGQ motif with better affinity than the parent antibody. The
latter should allow for a continuation of the assessment of the
accessibility of the V3 regions in non-subtype B viruses.
Broadening the specificity of mAbs has been demonstrated
with antibodies to the BAFF (B-cell activating factor of the
tumor necrosis factor family) receptor BR3 using phage
display (Lee et al., 2006) and, somewhat more recently,
Garcia-Rodriguez et al. used yeast display and a co-selection
strategy to increase the cross-reactivity of a single chain Fv
antibody to botulinum neurotoxin type A (Garcia-Rodriguez et
al., 2007). Given a recent report in which immunization with a
group M consensus envelope glycoprotein induced a some-
what broad neutralizing antibody response in which ∼50% of
the average serum neutralizing activity was attributable to anti-
V3 antibodies (Liao et al., 2006), information gained from our
current and future analyses may positively influence the
rational design of V3-based antigens and be valuable in
general to further define neutralizing epitopes on the HIV-1
envelope spike.Materials and methods
MAbs
The anti-V3 mAb F425-B4e8 was isolated from an HIV-1-
infected patient by fusion of mononuclear splenocytes with
HMMA human myeloma cells (Posner et al., 1987, 1989); mAb
F425-B4e8 resulted from a fusion of splenocytes stimulated
with Epstein Barr virus for 48 h (Cavacini et al., 2003).
Hybridomas were selected based on their specific reactivity
with HIV-infected cells and ability to capture a relatively high
degree of virions in a virus capture assay (Cavacini et al., 2003).
The general specificity of mAb F425-B4e8 for the V3 loop was
determined based on its binding profile with variable loop
deleted gp120 mutants (Cavacini et al., 2003).
MAb 447-52D, an anti-V3 mAb that is capable of
neutralizing a number of mainly subtype B viruses (Binley et
al., 2004; Conley et al., 1994), was included in the epitope
mapping analysis. This antibody was isolated from an HIV-1-
infected individual and selected based on its reactivity with a V3
peptide (Gorny et al., 1992, 1993). The core epitope of the
antibody has been mapped to the GPxR motif at the tip of the
V3 region, although some preference is exhibited for certain
residues in the N-terminal portion of the V3 stem, as judged by
its reactivity profile with phage-displayed peptides (Keller et al.,
1993).
Neutralization assays
MAbs were evaluated for their neutralization breadth by
employing a high-throughput luciferase-based single round of
infectivity assay with pseudotyped viruses and U87 target cells
expressing CD4, CCR5, and CXCR4 (Richman et al., 2003).
Serial dilutions of mAb, starting at 50 μg/ml, were incubated
for 1 h with virus after which the mixture was added to target
cells. The tested viruses (n=40) are shown in Table 1; they
included 3 clade A viruses, 4 CRF01_AE circulating re-
combinant forms, 16 clade B viruses, 11 clade C viruses, and
6 clade D viruses. All but one of the viruses (NL4.3) were a
primary viral strains. The viruses were selected from a 90-
member panel used in a recent study by Binley et al. (2004).
Most viruses were from quasispecies derived from primary
virus cultures. However, eight of the tested viruses were
molecular clones (Table 1); four of these clones were the same
as used previously in the Binley et al. study (Binley et al.,
2004), whereas the remaining four clones (BG1168, SS1196,
92BR020, and 92US712) were new (T. Wrin et al., unpub-
lished results); the neutralization sensitivity of these four latter
clones largely reflected the neutralization sensitivity of the
viral quasispecies to mAbs 2F5, 2G12, 4E10, and b12, and a
cross-neutralizing HIV+ plasma termed N16 (T. Wrin et al.,
unpublished results). To allow for comparison between the
results obtained in this study and the results obtained in the
Binley et al. study, we included mAb b12 in our analyses
(Barbas et al., 1992; Roben et al., 1994) because it neutralizes
a broad range of viruses (Binley et al., 2004; Li et al., 2005,
2006). MAb F425-B4e8 was also assessed for its ability to
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(see below), using an in-house luciferase-based assay with
U87 target cells expressing CD4 and CCR5 as described
previously (Pantophlet et al., 2003).
Quikchange mutagenesis
For epitope mapping, single amino acid substitutions in V3
were generated using relevant complementary primers by
Quikchange II XL mutagenesis (Stratagene) of the plasmid
pSVIII-JR-CSF, which expresses the entire env gene of the
primary isolate JR-CSF (Pantophlet et al., 2003). Amino acid
substitutions were verified by DNA sequencing.
Generation of V3 mutant pseudovirions
JR-CSF pseudovirions were obtained by transient co-
transfection of 293T cells with wild-type or mutant env plasmid
and the luciferase reporter plasmid pNL4.3.Luc.R−E− (obtained
from the NIH AIDS Research and Reference Reagent Program
and contributed by Nathaniel Landau (Connor et al., 1995; He et
al., 1995)) using FuGENE (Roche) or polyethylenimine
(Kirschner et al., 2006). The culture media were replaced with
fresh media ∼6 h after transfection when polyethylenimine was
used. Supernatants were collected 3 days post-transfection and
used immediately for neutralization assays or detergent was
added (Empigen; 1% v/v final concentration) and the viral
lysates used for ELISA (see below).
ELISAs
To compare the apparent binding affinities of the antibodies
for JR-CSF wild-type virus relative to the V3 mutants, ELISA
binding assays were performed as described before using
detergent-treated supernatants collected from transiently trans-
fected 293T cells (Pantophlet et al., 2003). Briefly, detergent-
containing supernatants, diluted so as to equalize the amount of
gp120 in each preparation, were added to ELISA plate wells
(Costar, #3690) coated at 5 μg/ml with a monospecific sheep
antibody preparation which binds to the C5 region of gp120
(Cliniqa). Anti-V3 mAbs were added to the ELISA plate wells
in 5-fold serial dilutions. MAb binding was detected with a
peroxidase-conjugated secondary antibody and TMB substrate
(Pierce). Absorbances were measured at 450 nm after stopping
the color reaction with sulfuric acid (2 M concentration).
Apparent affinities were determined as the antibody concentra-
tion at half-maximal binding based on ELISA binding curves
using the program Graphpad Prism (v. 4.0); antibody affinity for
each mutant gp120 relative to wild-type gp120 was calculated
as: (apparent affinity for wild-type gp120 /apparent affinity for
mutant gp120)×100.
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